EUVIMED · CrossrefZeitschrift
Pharmaceutical Patent Analyst
ISSN 2046-8954 · Informa UK Limited
Neueste Artikel
From supplements to superbugs: how probiotic patent gaps drive antimicrobial resistance and the CRISPR-Cas solutions
Proteolysis targeting chimeras (PROTACs) in oncology: a review of patents and regulatory considerations
Development in medicinal chemistry via oxadiazole derivatives: patent spotlight 2020–2024
Esterase responsive release of anti-cancer agents from conjugated lipid nanocarrier and the regulatory considerations
Recent Patents in the Treatment and Prevention of Leishmaniasis
Multicomponent Crystal Compromising Dasatinib and Selected Co-Crystals Formers: A Patent Evaluation of EP2861589B1
Patentability Challenges Associated with Emerging Pharmaceutical Technologies
Liposome-based Drug Delivery of Various Anticancer Agents of Synthetic and Natural Product Origin: a Patent Overview
Nonobviousness of Pharmaceutical Inventions: Implications for Patent Prosecution and Litigation
Therapeutic Charm of Quercetin and Its Derivatives: a Review of Research and Patents
Fluorine-18 Patents (2009–2015). Part 2: New Radiochemistry
IPAT: a Freely Accessible Software Tool for Analyzing Multiple Patent Documents With Inbuilt Landscape Visualizer
Medicinal Importance of Gallic Acid and Its Ester Derivatives: a Patent Review
Inhaled Antibiotics to Treat Lung Infection
Small-molecule Inhibitors of IκB Kinase (IKK) and IKK-related Kinases
The Impact of Effective Patents on Future Innovations in Nanomedicine
Catalyzing innovation in cancer drug discovery through artificial intelligence, machine learning and patency
Sulfopropanoic acid derivatives for treating neurodegenerative disorders: a patent spotlight
Liraglutide innovations: a comprehensive review of patents (2014–2024)
Insights to the emerging potential of glucokinase activators as antidiabetic agent
Patent highlights October–November 2023
3D-printed immediate release solid dosage forms: a patent evaluation of US11622940B2
Patent highlights December 2023–January 2024
Patent highlights February–March 2024
Contradicting rulings of the US patent office on double patenting jeopardize the generic and biosimilar drugs
Emerging patents versus brain eating amoebae, Naegleria fowleri
Patent highlights June — July 2024
Patent highlights April–May 2024
Developments in research and commercialization of PI3K and AKT targets: a patent-based landscape
PLGA and cancer: a comprehensive patent-based review on the present state of art
EUVIMED